Sonoma Pharmaceuticals, Inc. — Director's Dealing 2012

Mar 9, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oculus Innovative Sciences, Inc. (OCLS)
CIK: 0001367083
Period of Report: 2012-03-07

Reporting Person: Schutz James J (Director, Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-03-07	Stock Option (Right to Buy)	$1.25	A	187500	Acquired	2022-03-07	Common Stock (187500)	Direct

Footnotes

F1: The option vests immediately as to 78,000 shares, and will vest 1/36th per month over a three year vesting schedule commencing on the date of grant as to the remaining 109,500 shares.

F2: The option grant was made pursuant to the Issuer's 2011 Bonus Plan.